Core Viewpoint - The A-share market experienced a significant decline on November 21, with over 5,000 stocks falling, leading to a 2.45% drop in the Shanghai Composite Index, which fell below 3,900 points, and a 4.02% drop in the ChiNext Index [1] Group 1: Market Performance - The securities sector followed the market trend, with the leading securities ETF (560090) dropping 3.45%, reflecting a bearish sentiment with two consecutive days of decline [1] - Despite the overall market downturn, the securities ETF (560090) attracted over 100 million yuan in capital inflow over the past five days, indicating active buying interest [1] Group 2: Securities Sector Analysis - Nearly all component stocks of the securities ETF (560090) experienced declines, with notable drops including over 5% for Industrial Securities and over 4% for Huatai Securities and GF Securities [3] - The securities sector has seen a slight decline of 0.79% year-to-date, but the net profit growth for the first three quarters reached 62%, highlighting its high growth potential despite current low valuations [5] Group 3: M&A Activity and Future Outlook - The recent merger activity, particularly the absorption of Dongxing Securities and Xinda Securities by China International Capital Corporation (CICC), is expected to reignite investor interest in securities stocks [6][7] - Analysts are optimistic about the long-term growth potential and valuation recovery of the securities sector, driven by active market trading and a stable capital market environment [7][8]

Group 1: Core Insights - The average price of broiler chicks in major production areas in October is 3.35 CNY per chick, down 19.3% year-on-year but up 2.4% month-on-month, indicating a challenging environment for white feather chicken farming [1] - The average price of live chickens is 6.93 CNY per kilogram, down 6.8% year-on-year and 0.9% month-on-month, with a loss of 1.78 CNY per chick in the farming sector [1] - The supply of parent stock broiler chicks is expected to tighten in the second half of 2025 due to a significant decrease in overseas imports, which will also impact the supply of commercial broiler chicks in 2026 [1] Group 2: Yellow Feather Chicken Insights - The average price of fast-growing yellow chickens in October is 4.82 CNY per jin, down 6.4% year-on-year and 10.9% month-on-month, while the average price of Xueshan grass chickens is 7.68 CNY per jin, down 13% year-on-year and 14.2% month-on-month [2] - Despite a slight decline in demand post-holidays, yellow chicken prices remain stable, and profitability in the farming sector is still favorable [2] - Major companies have reduced their yellow chicken production costs, with Wens' cost at approximately 5.8 CNY per jin and Lihua's potentially below 5.7 CNY per jin [2] Group 3: Future Outlook - The demand for quality parent stock broiler chicks is expected to remain strong in 2025, despite an increase in imports of grandparent stock chickens in 2024 [3] - The current low inventory of parent stock chickens and ongoing industry losses are setting the stage for future price increases in yellow chickens [3] - The market for fresh yellow feather chickens is anticipated to have significant growth potential due to changing consumer habits and economic recovery [3]

一、董事/高级管理人员离任情况 | 是否存在 | 是否继续在上 | 原定任期到 | 离任原 | 具体职务 | 未履行完 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 离任职务 | 离任时间 | 市公司及其控 | 期日 | 因 | （如适用） | 毕的公开 | 股子公司任职 | | | | | | | | 承诺 | | | | | | | | | | | | | | | | 2025 | 年 | 11 | 2027 | 年 | 1 | 月 | 到 | 龄 | 退 | 刘辉 | 非执行董事 | 否 | 无 | 否 | | 月 | 21 | 日 | 18 | 日 | 休 | | | | | | | | | | (一) 提前离任的基本情况 (二) 离任对公司的影响 招商证券股份有限公司（以下简称公司）董事会于 2025 年 11 月 21 日收到 公司非执行董事刘辉女士递交的书面辞职报告。因到龄退休原因，刘辉女士申请 辞去公司第 ...

Core Viewpoint - The report from China Merchants Securities indicates that in Q3 2025, the profitability of listed pig companies has significantly declined due to falling pig prices and rising raw material costs, while the cost variance within the industry remains substantial, leading to an expansion of cost advantages for high-quality pig companies. The overall demand is showing signs of recovery in the later cycle, suggesting a potential increase in pig prices in 2026 due to accelerated sow capacity reduction [1][2]. Group 1: Swine Farming - In Q3 2025, the profitability of 18 listed pig companies dropped to 5.54 billion yuan, reflecting a year-on-year decrease of 71% and a quarter-on-quarter decrease of 38% [2]. - The cost variance in the industry remains significant, with high-quality pig companies further enhancing their cost advantages [2]. - The operational cash flow of listed pig companies continues to improve, while capital expenditures remain low and debt ratios are high [2]. - The report anticipates an acceleration in sow capacity reduction, which may elevate the average pig price in 2026 [2]. - Recommended companies include Muyuan Foods and Wens Foodstuff Group, with additional attention on Shennong Group, Dekang Agriculture, Dongrui Co., and COFCO Joycome [2][5]. Group 2: Poultry Farming - The white feather chicken market is expected to see an increase in the import of grandparent stock chickens in 2024, but it will not return to pre-disruption levels until 2025 [3]. - The supply of parent stock chickens is expected to tighten in the second half of 2025, impacting the supply of commercial chickens in 2026 [3]. - The yellow feather chicken sector is experiencing a reduction in parent stock numbers to historically low levels, which may support future price increases [3]. - Recommended companies in poultry farming include San Nong Development for white feather chickens and Lihua Food for yellow feather chickens [3][5]. Group 3: Post-Cycle Demand - The demand for feed in the swine and poultry sectors is gradually recovering, leading to a notable improvement in feed demand [4]. - The demand for aquaculture feed is also expected to rise as the aquaculture sector recovers [4]. - The report forecasts continued demand growth for livestock feed in Q4 2025, while aquaculture feed demand may enter a seasonal decline [4]. - Recommended companies for feed include Haida Group, which is expected to benefit from overseas expansion [4][5]. - In the animal health sector, demand is recovering due to sustained profitability in the downstream farming sector, with major animal health companies expected to see improved profitability [4]. Recommended companies include Kexin Biological and attention on BioStock and Reap Biological [4][5].

南财智讯11月21日电，招商证券公告，公司董事会于2025年11月21日收到非执行董事刘辉女士递交的书 面辞职报告。因到龄退休原因，刘辉女士申请辞去公司第八届董事会非执行董事、董事会战略与可持续 发展委员会委员、董事会风险管理委员会委员及董事会薪酬与考核委员会委员职务。刘辉女士的辞任自 其辞职报告送达公司董事会时生效。 ...

中国经济网北京11月21日讯 昨日，招商证券资产管理有限公司公告，李传真离任招商资管中证全 指自由现金流指数发起、招商资管核心优势混合。 李传真现任招商资管基金经理，曾任招商资管高端制造行业研究员，负责中游制造行业的研究，历 任安信证券资产管理部权益研究员，投资经理助理。2023年6月12日起任招商资管基金经理。 | 基金名称 | 招商资管核心优势混合型证券投资基金 | | --- | --- | | 基金简称 | 招商资管核心优势混合 | | 基金主代码 | 880006 | | 基金管理人名称 | 招商证券资产管理有限公司 | | 公告依据 | 《公开募集证券投资基金信息披露管理办法》《基 | | | 金管理公司投资管理人员管理指导意见》 | | 基金经理变更类型 | 兼有增聘和解聘基金经理 | | 新任基金经理姓名 | 蔡霖 | | 共同管理本基金的其他基金 | | | 经理姓名 | | | 离任基金经理姓名 | 李传真 | （责任编辑：康博） 招商资管中证全指自由现金流指数发起A/C成立于2025年9月12日，截至2025年11月20日，成立来 收益率为7.43%、7.40%。 招商资管核心优势混合A ...

Group 1 - The core viewpoint of the report indicates that H&H International Holdings (01112) achieved a revenue of 10.805 billion yuan in Q1-3 of 2025, representing a year-on-year increase of 12.3%, with Q3 revenue reaching 3.786 billion yuan, up 28.5%, exceeding market expectations [1][3] - In terms of regional performance, the Chinese market accounted for 71.0% of total revenue in the first three quarters, showing a year-on-year growth of 20.6%. The Australia-New Zealand market declined by 19.4%, primarily due to a drop in purchasing agent business, while North America saw a growth of 5.9%, and other markets grew by 19.0%, with nine expanding Asian markets showing a remarkable growth of 64.4% [1] - The company's ANC (Adult Nutrition Category) business generated revenue of 5.243 billion yuan in Q1-3, up 6.0% year-on-year, with Q3 revenue of 1.804 billion yuan, increasing by 6.3%. Swisse maintained its position as the leading brand in the all-channel nutrition and health product market in mainland China, with a year-on-year revenue growth of 15.7% [1][3] Group 2 - The BNC (Baby Nutrition Category) revenue reached 3.973 billion yuan in Q1-3, reflecting a year-on-year increase of 24.0%, with Q3 revenue soaring to 1.471 billion yuan, up 90.6%. The significant growth in infant formula was attributed to the transition to new national standards and effective strategies in maternal education and channel investment [2] - The market share of the company's premium infant formula brand, Gan Shen Yuan, reached 16.4% in the first nine months, further increasing to 17.3% in Q3. Revenue from infant probiotics and nutritional products grew by 58.8% in Q3, with the decline in revenue narrowing to 2.3% over the first nine months [2] - The report anticipates that the EBITDA margin for the BNC business will rebound to 12%-15% due to strong growth in infant formula and the successful completion of the new national standard transition [2]

Group 1 - Chinese brokerage stocks experienced a widespread decline, with Dongfang Securities down 4.28% at HKD 6.94, China Merchants Securities down 4.11% at HKD 14.47, CITIC Securities down 3.67% at HKD 12.09, and Guolian Minsheng down 3.08% at HKD 5.35 [1] - The Federal Reserve's October monetary policy meeting minutes indicated significant disagreement among officials regarding potential interest rate cuts in December, amidst moderate economic expansion and a cooling labor market [1] - Analysts from CITIC Futures noted that the core drivers for major assets this week are the "anticipatory rush" following the U.S. government reopening and the strengthening expectations of increased liquidity [1] Group 2 - China International Capital Corporation (CICC), Dongxing Securities, and Xinda Securities announced a suspension of trading to plan a merger, with CICC set to absorb the other two firms through a share swap [2] - Non-bank analyst Bo Xiaoxu from China Aviation Securities highlighted that regulatory encouragement for industry consolidation aligns with the trend of promoting high-quality development in the securities sector, making mergers and acquisitions an effective means for brokerages to achieve external growth [2] - The consolidation within the brokerage industry is expected to enhance overall competitiveness, optimize resource allocation, and promote healthy market development, while also increasing industry concentration and creating economies of scale [2]

Core Viewpoint - The 2025 China Securities Industry Investment Banking Summit Forum highlighted the transformation strategies of investment banks amid capital market changes, with a focus on the resurgence of Chinese enterprises listing in Hong Kong and the anticipated growth in IPO activities in 2025 [2]. Group 1: Market Trends - Since the second half of 2024, there has been a notable recovery in Chinese enterprises listing in Hong Kong, with a projected increase in IPO issuance in 2025, leading to a financing scale that is expected to rise by over 200% year-on-year [2]. - The average first-day increase for IPO companies is reported at 59.3%, indicating strong market performance [2]. - The hot trend in the Hong Kong stock market is expected to continue until 2026, presenting cross-border business opportunities for Chinese investment banks [2]. Group 2: Strategic Focus - Domestic investment banks are adopting "regional deep cultivation" and "track specialization" as their two core strategies to reshape the competitive landscape [2]. - Changjiang Securities has been exploring iterative deep cultivation models and plans to enhance its role as a "guide" for industries by serving local platform companies and forming funds to attract quality enterprises along the industrial chain [2]. Group 3: Forum Discussions - The forum featured two roundtable discussions focusing on investment banking strategic transformation and the integration of technology and finance [3]. - Key executives from various securities firms participated in discussions about navigating cycles and embracing new production capabilities in the context of technology finance [3]. Group 4: Awards - The forum also announced the results of the "2025 China Securities Industry Investment Banking Jun Ding Award," recognizing outstanding contributions in various categories, including underwriting and sponsorship [5][6][7][8][10][11][13][14][21].

Company Background - Founded in 1993, the company is a leading biopharmaceutical firm in China with extensive experience in R&D, production, and sales of biological drugs. It has developed a rich product portfolio and pipeline in various therapeutic areas including nephrology, hematology, oncology, autoimmune diseases, and dermatology [1] - The company has strong domestic commercialization capabilities, with core products such as TPIAO, EPO, Yisaipu, and Mandi holding high market shares, driving continuous revenue growth [1] Oncology Focus - The SSGJ-707 molecule is expected to become a cornerstone therapy in global cancer immunotherapy, with multiple first-in-class (FIC) molecules entering clinical stages. A significant licensing agreement with Pfizer was established in May-July 2025, where Pfizer will pay $1.4 billion upfront and up to $4.8 billion in milestone payments, setting a record for domestic PD-(L)1/VEGF dual antibodies [1][2] - The PD-(L)1 inhibitors face challenges in cold tumors and efficacy improvements, but the dual antibody approach has shown potential in head-to-head trials against existing therapies, indicating a market potential exceeding $100 billion [1] Clinical Development Plans - Pfizer's strategy for SSGJ-707 includes launching seven global clinical trials, positioning it as a foundational therapy across various cancers. Upcoming trials include 1L NSCLC Phase III, 1L mCRC Phase III, and others, with plans to explore over 10 additional indications by 2026 [2] - The potential market for SSGJ-707 could cover over 350,000 patients in the U.S., indicating a substantial market opportunity [2] Commercialization Strength - The company has a strong commercial capability with its flagship product TPIAO projected to generate revenue of 5.06 billion yuan in 2024. TPIAO is the only commercialized rhTPO globally and is highly recommended in treatment guidelines [3] - Despite competitive pressures, the company maintains a leading position in the rhEPO market, with expected sales of 1.019 billion yuan from its dual-brand strategy in 2024, capturing a 42% market share [3] Financial Projections - Revenue forecasts for the company are estimated at 18.52 billion yuan in 2025, 11.55 billion yuan in 2026, and 11.78 billion yuan in 2027, with net profits projected at 9.77 billion yuan, 3.72 billion yuan, and 3.28 billion yuan respectively. The company is rated with a strong recommendation based on these projections [4]